Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2002 Apr;11(2):87–93. doi: 10.1080/09629350220131935

Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.

Cem Evereklioglu 1, Hamdi Er 1, Yusuf Türköz 1, Mustafa Cekmen 1
PMCID: PMC1781647  PMID: 12061429

Abstract

AIM: Behçet's disease (BD) is asystemic immunoinflammatory disorder and the aetiopathogenesis is to be specified. Cytokines play a role in immune response and in many inflammatory diseases. The aim of this case-control study is to investigate serum pro-inflammatory cytokine tumour necrosis factor (TNF)-alpha, interleukin-1beta (IL-1beta), soluble IL-2 receptor (sIL-2R), IL-6, and chemokine IL-8 levels in patients with BD. We also determined the end product of lipid peroxidation (malondialdehyde (MDA)) in BD patients as an index for oxidative stress. METHODS: A total of 37 patients (19 men, 18 women) with BD (active, n = 17; inactive, n = 20) and 20 age-matched and sex-matched healthy control subjects (11 men, nine women) included in this cross-sectional, blinded study. Serum TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels were determined by a spectrophotometer technique using the immulite chemiluminescent immunometric assay. Lipid peroxidation was evaluated by Wasowicz et aL The levels of cytokines and lipid peroxidation in the active period were compared with the inactive period of the disease. Results are expressed as mean +/- standard error. RESULTS: IL-1beta levels were below the detection limits of the assay (< 5 pg/ml) in all samples. Mean levels of MDA (8.1+/-0.7 micromol/l), sIL-2R (800+/-38 U/ml), IL-6 (12.6+/-1.1 pg/ml), IL-8 (7.2+/-0.4 pg/ml), and TNF-alpha (7.9+/-0.5 pg/ml) in active BD patients were significantly higher than those in inactive patients (4.3+/-0.5 micromol/l, p < 0.01; 447+/-16 U/ml, p < 0.001; 8.3+/-0.6 pg/ml, p = 0.006; 5.3+/-0.1 pg/ml, p < 0.001; and 5.1 0.2 pg/ml, p < 0.001; respectively) or control subjects (2.1+/-0.2 micromol/l, p < 0.001; 446+/-20 U/ml, p < 0.001; 6.4+/-0.2 pg/ml, p < 0.001; 5.4+/-0.1 pg/ml, p < 0.001; and 4.7+/-0.1 pg/ml, p < 0.001, respectively). On the contrary, only the mean IL-6 level was significantly different between inactive BD and control subjects (p = 0.02). All acute phase reactants were significantly higher in active BD than in inactive period (for each, p < 0.01). Conclusions: High levels of sIL-2R, IL-6, IL-8 and TNF-alpha indicate the activation of immune system in BD. Serum sIL-2R, IL-6, IL-8 and TNF-alpha seem to be related to disease activity. Increased lipid peroxidation suggests oxidative stress in BD and therefore tissue damage in such patients. Amelioration of clinical manifestations would be envisaged by targeting these cytokines, chemokines and lipid peroxidation with pharmacological agents.

Full Text

The Full Text of this article is available as a PDF (185.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baggiolini M., Walz A., Kunkel S. L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989 Oct;84(4):1045–1049. doi: 10.1172/JCI114265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Balkwill F. R., Burke F. The cytokine network. Immunol Today. 1989 Sep;10(9):299–304. doi: 10.1016/0167-5699(89)90085-6. [DOI] [PubMed] [Google Scholar]
  3. Ballow M., Nelson R. Immunopharmacology: immunomodulation and immunotherapy. JAMA. 1997 Dec 10;278(22):2008–2017. doi: 10.1001/jama.278.22.2008. [DOI] [PubMed] [Google Scholar]
  4. Berthier F., Lambert C., Genin C., Bienvenu J. Evaluation of an automated immunoassay method for cytokine measurement using the Immulite Immunoassay system. Clin Chem Lab Med. 1999 May;37(5):593–599. doi: 10.1515/CCLM.1999.092. [DOI] [PubMed] [Google Scholar]
  5. Bloch-Michel E., Nussenblatt R. B. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987 Feb 15;103(2):234–235. doi: 10.1016/s0002-9394(14)74235-7. [DOI] [PubMed] [Google Scholar]
  6. Chambers J. C., Haskard D. O., Kooner J. S. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome. J Am Coll Cardiol. 2001 Feb;37(2):517–520. doi: 10.1016/s0735-1097(00)01137-2. [DOI] [PubMed] [Google Scholar]
  7. Dinarello C. A. Interleukin-1 and interleukin-1 antagonism. Blood. 1991 Apr 15;77(8):1627–1652. [PubMed] [Google Scholar]
  8. Dinarello C. A. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med. 1984 Nov 29;311(22):1413–1418. doi: 10.1056/NEJM198411293112205. [DOI] [PubMed] [Google Scholar]
  9. Evans C. A., Jellis J., Hughes S. P., Remick D. G., Friedland J. S. Tumor necrosis factor-alpha, interleukin-6, and interleukin-8 secretion and the acute-phase response in patients with bacterial and tuberculous osteomyelitis. J Infect Dis. 1998 Jun;177(6):1582–1587. doi: 10.1086/515313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Evereklioglu C., Cokkeser Y., Doganay S., Er H., Kizilay A. Audio-vestibular evaluation in patients with Behçet's syndrome. J Laryngol Otol. 2001 Sep;115(9):704–708. doi: 10.1258/0022215011908946. [DOI] [PubMed] [Google Scholar]
  11. Evereklioglu C., Er H. Increased corneal thickness in active Behçet's disease. Eur J Ophthalmol. 2002 Jan-Feb;12(1):24–29. doi: 10.1177/112067210201200105. [DOI] [PubMed] [Google Scholar]
  12. Evereklioglu C., Yurekli M., Er H., Ozbek E., Hazneci E., Cekmen M., Inaloz H. S. Increased plasma adrenomedullin levels in patients with Behçet's disease. Dermatology. 2000;201(4):312–315. doi: 10.1159/000051544. [DOI] [PubMed] [Google Scholar]
  13. Evereklioglu Cem, Turkoz Yusuf, Er Hamdi, Inaloz H. Serhat, Ozbek Emin, Cekmen Mustafa. Increased nitric oxide production in patients with Behçet's disease: is it a new activity marker? J Am Acad Dermatol. 2002 Jan;46(1):50–54. doi: 10.1067/mjd.2002.118338. [DOI] [PubMed] [Google Scholar]
  14. Ghate J. V., Jorizzo J. L. Behçet's disease and complex aphthosis. J Am Acad Dermatol. 1999 Jan;40(1):1–20. doi: 10.1016/s0190-9622(99)70523-2. [DOI] [PubMed] [Google Scholar]
  15. Guemouri L., Artur Y., Herbeth B., Jeandel C., Cuny G., Siest G. Biological variability of superoxide dismutase, glutathione peroxidase, and catalase in blood. Clin Chem. 1991 Nov;37(11):1932–1937. [PubMed] [Google Scholar]
  16. Gunen H., Evereklioglu C., Kosar F., Er H., Kizkin O. Thoracic involvement in Behçet's disease and its correlation with multiple parameters. Lung. 2000;178(3):161–170. doi: 10.1007/s004080000019. [DOI] [PubMed] [Google Scholar]
  17. Heinrich P. C., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990 Feb 1;265(3):621–636. doi: 10.1042/bj2650621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hoekzema R., Murray P. I., Kijlstra A. Cytokines and intraocular inflammation. Curr Eye Res. 1990;9 (Suppl):207–211. doi: 10.3109/02713689008999443. [DOI] [PubMed] [Google Scholar]
  19. Ikeda U., Ikeda M., Minota S., Shimada K. Homocysteine increases nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells. Circulation. 1999 Mar 9;99(9):1230–1235. doi: 10.1161/01.cir.99.9.1230. [DOI] [PubMed] [Google Scholar]
  20. Jorizzo J. L., Hudson R. D., Schmalstieg F. C., Daniels J. C., Apisarnthanarax P., Henry J. C., Gonzalez E. B., Ichikawa Y., Cavallo T. Behçet's syndrome: immune regulation, circulating immune complexes, neutrophil migration, and colchicine therapy. J Am Acad Dermatol. 1984 Feb;10(2 Pt 1):205–214. doi: 10.1016/s0190-9622(84)70024-7. [DOI] [PubMed] [Google Scholar]
  21. Kapp A., Piskorski A., Schöpf E. Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. Br J Dermatol. 1988 Dec;119(6):707–710. doi: 10.1111/j.1365-2133.1988.tb03491.x. [DOI] [PubMed] [Google Scholar]
  22. Leonard E. J., Yoshimura T. Neutrophil attractant/activation protein-1 (NAP-1 [interleukin-8]). Am J Respir Cell Mol Biol. 1990 Jun;2(6):479–486. doi: 10.1165/ajrcmb/2.6.479. [DOI] [PubMed] [Google Scholar]
  23. Nathan C., Xie Q. W. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994 Sep 23;78(6):915–918. doi: 10.1016/0092-8674(94)90266-6. [DOI] [PubMed] [Google Scholar]
  24. Sahin S., Akoğlu T., Direskeneli H., Sen L. S., Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet's disease. Ann Rheum Dis. 1996 Feb;55(2):128–133. doi: 10.1136/ard.55.2.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Symons J. A., Wood N. C., Di Giovine F. S., Duff G. W. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol. 1988 Oct 15;141(8):2612–2618. [PubMed] [Google Scholar]
  26. Wasowicz W., Nève J., Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. Clin Chem. 1993 Dec;39(12):2522–2526. [PubMed] [Google Scholar]
  27. Wechsler B., Lê Thi Huong Du L. T., de Gennes C., Blétry O., Piette J. C., Mathieu A., Kieffer E., Godeau P. Manifestations artérielles de la maladie de Behçet. Douze observations. Rev Med Interne. 1989 Jul-Aug;10(4):303–311. doi: 10.1016/s0248-8663(89)80027-x. [DOI] [PubMed] [Google Scholar]
  28. Yokoyama T., Kanda T., Kobayashi I., Suzuki T. Serum levels of interleukin-8 as a marker of disease activity in patients with chronic sarcoidosis. J Med. 1995;26(5-6):209–219. [PubMed] [Google Scholar]
  29. de Vos A. F., Klaren V. N., Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3873–3883. [PubMed] [Google Scholar]
  30. de Vos A. F., van Haren M. A., Verhagen C., Hoekzema R., Kijlstra A. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci. 1994 Mar;35(3):1100–1106. [PubMed] [Google Scholar]
  31. di Giovine F. S., Duff G. W. Interleukin 1: the first interleukin. Immunol Today. 1990 Jan;11(1):13–20. doi: 10.1016/0167-5699(90)90005-t. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES